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Summary
NADPH-cytochrome P450 reductase transfers two re-
ducing equivalents derived from a hydride ion of
NADPH via FAD and FMN to the large family of micro-
somal cytochrome P450 monooxygenases in one-
electron transfer steps. The mechanism of electron
transfer by diflavin reductases remains elusive and
controversial. Here, we determined the crystal struc-
ture of truncated yeast NADPH-cytochrome P450 re-
ductase, which is functionally active toward its physi-
ological substrate cytochrome P450, and discovered
a second FMN binding site at the interface of the con-
necting and FMN binding domains. The two FMN bind-
ing sites have different accessibilities to the bulk
solvent and different amino acid environments, sug-
gesting stabilization of different electronic structures
of the reduced flavin. Since only one FMN cofactor is
required for function, a hypothetical mechanism of
electron transfer is discussed that proposes shuttling
of a single FMN between these two sites coupled with
the transition between two semiquinone forms, neu-
tral (blue) and anionic (red).
Introduction
The mechanism of electron transfer by diflavin reduc-
tases remains both elusive and controversial despite
extensive studies including kinetic, spectroscopic, crys-
tallographic, and site-directed mutagenesis techniques
(Murataliev et al., 2004). Mechanisms proposed for mam-
malian (Backes, 1993) and other (Murataliev et al., 1997,
1999; Murataliev and Feyereisen, 1999; Sevrioukova
et al., 1996a) NADPH-cytochrome P450 reductases
(CPRs) disagree in (1) the number of electrons residing
on flavins during the catalytic cycle, in (2) the require-
ment for a priming reaction by NADPH, and in (3) the ac-
tive form of the FMN that serves as donor of electrons.
Within the cell, CPR is anchored to the endoplasmic
reticulum through a single N-terminal amino acid seg-
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4 These authors contributed equally to this work.ment and transfers electrons from NADPH to its major
physiological acceptors, the ubiquitous family of micro-
somal cytochrome P450 monooxygenases (P450, CYP),
as well as to squalene monooxygenase (Laden et al.,
2000; Ono and Bloch, 1975), heme oxygenase (Schacter
et al., 1972), fatty acid desaturase (Ilan et al., 1981), and
cytochrome b5 (Enoch and Strittmatter, 1979). In vitro,
CPR can donate electrons to the nonphysiological elec-
tron acceptor cytochrome c (Williams and Kamin, 1962)
and to a variety of small-molecule dyes. Microsomal
CPRs belong to a family of electron transporters that
includes the Bacillus megaterium cytochrome P450
(P450BM3) reductase (Narhi and Fulco, 1986) and related
homologs from Bacillus subtilis (Gustafsson et al., 2004)
and Fusarium oxysporum (Kitazume et al., 2000), as well
as nitric oxide synthases (Bredt et al., 1991), methionine
synthase reductase (Leclerc et al., 1998), novel reduc-
tase 1 (Paine et al., 2000), and the a subunit of bacterial
sulfite reductases (Ostrowski et al., 1989). The common
feature of these reductases is the presence of two flavin
prosthetic groups, FAD and FMN, which channel elec-
trons from NADPH to metal ion centers. During a catalytic
cycle, CPR transfers a hydride ion derived from NADPH
to FAD, and the latter transfers electrons to FMN, from
where they are delivered to acceptor proteins in two
one-electron transfer steps. Diflavin reductases share
significant sequence homology with two classes of fla-
voproteins, prokaryotic FMN-containing flavodoxin and
FAD-containing ferredoxin-NADP+ reductase (Porter
and Kasper, 1985). This fact led to the hypothesis that di-
flavin reductases evolved as fusion proteins of the two
bacterial monoflavin electron transport enzymes (Porter
and Kasper, 1986). A connecting domain, unique for di-
flavin reductases, tethers the flavin binding domains
close to each other to maximize electronic coupling
(Coves et al., 1997; Sevrioukova et al., 1996b; Smith et al.,
1994). Indeed, Escherichia coli flavoproteins, flavodoxin,
and NADPH-flavodoxin reductase can serve as an elec-
tron transfer system for microsomal P450, although
with rates an order of magnitude lower than CPR (Jen-
kins and Waterman, 1998).
When separately expressed, FAD/NADPH and FMN
binding domains of human and rat reductases (Smith
et al., 1994), P450BM3 (Sevrioukova et al., 1997), and
the E. coli sulfite reductase (Coves et al., 1997) reconsti-
tute very low (0%–6%) catalytic activities of P450 and
nonphysiological partners. The low level of CPR activity
obtained by combining the individual reductase do-
mains may suggest that evolution leaned toward fused
diflavin reductases, resulting in a conceptually new elec-
tron transport mechanism rather than in a simple sum of
properties of the two individual monoflavin ancestors.
The only resolved CPR crystal structure to date that
shows the interactions between all structural domains
is that for N-terminal truncated rat CPR (rCPR) (Wang
et al., 1997). However, a limitation of this structure
comes from the fact that although truncated rCPR can
reduce cytochrome c, it is totally inactive toward re-
ducing P450s or other endogenous physiological part-
ners. In contrast, N-terminal-truncated Saccharomyces
Structure
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crystal structure in the present paper can complement
S. cerevisiae cells with a disrupted CPR gene to recon-
stitute ergosterol biosynthesis (Venkateswarlu et al.,
1998). Purified yCPR supports cytochrome c reduction
(Lamb et al., 2001) as well as CYP51 sterol 14a-demethy-
lase and CYP61 sterol 22-desaturase activities (Lamb
et al., 1999, 2001; Venkateswarlu et al., 1998). In a search
for structural determinants allowing physiological elec-
tron transfer between CPR and P450, we determined
the crystal structure of yCPR at 2.9 A˚ resolution. The
structure suggests a mechanism of electron transfer in
CPR whereby a single FMN molecule shuttles between
two protein sites and two flavin electronic states and re-
leases electrons to the acceptor from the second, newly
discovered site. The mechanism may be conserved
throughout evolution for eukaryotic diflavin reductases.
Results and Discussion
Functional Activity of yCPR
In reconstituted assays, the truncated yCPR used to ob-
tain crystals supported the catalytic activity of human
CYP51 and rabbit CYP1A2 (Figures 1A–1C), although
less efficiently than full-length rat CPR. Thus, lanosterol
demethylation by human CYP51 driven by yCPR was
almost ten times slower than that by full-length rat
CPR (Figure 1A), and it was comparable with the turn-
over rates for endogenous yeast partners, CYP51 and
CYP61, obtained elsewhere (Lamb et al., 1999; Venka-
teswarlu et al., 1998). In the CYP1A2 catalytic assay,
concentrations of yCPR an order of magnitude higher
compared to the full-length rat reductase were used to
obtain equal amounts of O-demethylated 7-methoxyre-
sorufin (Figure 1B). However, even this reduced func-
tional activity of yCPR is in direct contrast to the trun-
cated form of rat CPR, which is unable to support any
P450 activities (Wang et al., 1997). This difference is
somewhat surprising because overall rms deviations
for backbone atoms between yCPR and rCPR in the
crystal structures are within 1.44 A˚, which indicates a
high similarity between these two proteins.
The Connecting Domain in yCPR Binds FMN
and FAD Cofactors
The most striking feature of the yCPR compared to
the rCPR is the presence of a second FMN cofactor
(FMN2) bound to the interface of the connecting and
the FMN binding domains (Figure 2A), so that the dime-
thylbenzene edge of the FMN2 isoalloxazine, specifi-
cally the 8-CH3 group, protrudes from below the protein
surface toward two nearby acidic clusters, 186D-D187
and 193D-E-D195 (207D-D-D209 and 213E-E-D215 in the
rCPR), a surface to which cytochrome c and P450 are
mapped to bind (Nisimoto, 1986; Nisimoto and Otsuka-
Murakami, 1988; Shen and Kasper, 1995) (Figure 2B).
Another notable feature that distinguishes the yeast
and rat CPR structures is the conformation of the FAD
adenosine moiety, which in yCPR is bound between res-
idues P365 and Y405 in a hydrophobic pocket in the
connecting domain (Figure 2C). However, in rCPR, it is
exposed to the large opening within the protein interior,
where it can potentially clash with the phosphate group
of FMN2. Hence, in yCPR, the plane of the isoalloxazinering of FMN2 is orientated atw60º from the FAD adeno-
sine moiety and is separated from it by a residue of the
connecting domain P365 (si face of FMN2). The Y75 of
the FMN binding domain is on the re face of FMN2. In
rCPR, spatial hindrance created by the bulk of the FAD
adenosine may prevent FMN from binding in the FMN2
A
B
C
Figure 1. Functional Activity Assays
(A) Time course of lanosterol 14a-demethylation by human CYP51
driven by full-length rat and truncated yeast CPR. CYP51 is at a con-
centration of 2 mM, and both reductases are at a concentration of
4 mM. Turnover numbers are indicated below each curve and are
given in nmol product formed/min/nmol CYP51.
(B) O-demethylation of 7-methoxyresorufin by rabbit CYP1A2. Con-
centrations of CYP1A2 were 20 mM for yCPR and 2 mM for full-length
rat CPR-driven reactions.
(C) Functional activity of the yCPR mutants in lanosterol 14a-deme-
thylation by human CYP51.
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(A) Stereoview of the overall yCPR structure with four cofactors bound: FMN1, purple; FMN2, blue; FAD, yellow; NADPH, magenta. FMN2 is
closer to the viewer and is located between the FMN binding domain (green) and the connecting domain (rose). 7- and 8-CH3 groups of the
FMN2 point toward the viewer. 7- and 8-methyl groups of FMN1 point toward the same groups of the FAD. The FAD/NADPH binding domain
is shown in cyan.
(B) A surface view of the structure in the same color scheme and same orientation as in (A). Negatively charged clusters of residues involved in
cytochrome c and P450 binding are in red. The FMN2 (blue) is clearly visible through the bowl opening. Its 8-CH3 group points though the opening
toward the bulk solvent.
(C) Superimposition of FAD in the yCPR (yellow) and FAD in the rCPR (green). The electron density for FAD in the yCPR is represented by a frag-
ment of the 2Fo2 Fc composite omit map contoured at 1.8s. The FAD adenosine moiety in the yCPR is bound in a hydrophobic pocket formed by
residues of the connecting (rose) and the FAD/NADPH binding (cyan) domains.site despite the fact that the isoalloxazine binding por-
tion of the FMN2 site is well-defined, and excess FMN
was used to obtain the rCPR crystals (Wang et al., 1997).
The FMN1 Site
The FMN1 site is located in the CPR flavodoxin domain
and is buried within the CPR interior. The FMN1 site is
well conserved among all CPRs (Figure 3). The FMN1
isoalloxazine ring in yCPR is bound between aromatic
residues Y118 (re face) and Y157 (si face), while F160
and F159 are at the pyrimidine edge (Figure 4A). Addi-
tional contacts between the isoalloxazine ring and
the apoprotein are with backbone residues 116S-G119
and 153G-N161. The hydroxyl groups of the ribityl moiety
are 4 A˚ away from the invariant D187. The FMN1 phos-
phate is hydrogen bonded to the hydroxy amino acid
S67, S116, and Y118 side chains, and to the back-
bone amide groups of the conserved quintet of resi-
dues Q68T69G70T71A/G72. As in flavodoxins, the negative
charge on the phosphate is not neutralized by positively
charged amino acids. As a result of this neutral and
hydrophobic environment, flavin semiquinone is highlystabilized in flavodoxins at its neutral form (Mayhew and
Tollin, 1992), an exception being the isolated P450BM3
flavodoxin domain, which was reported to stabilize an
anionic (red) FMN semiquinone (Hanley et al., 2004).
Given that the protein backbone is primarily involved in
the interactions with the FMN1 isoalloxazine ring, the
electronic structure and, consequently, the redox prop-
erties of the FMN bound in this site are expected to be
similar between CPRs. High sequence similarity in
FMN1 binding regions conflicts with the direct and indi-
rect estimations of the reduction potentials of diverse
CPRs, demonstrating that the reduction potentials of
both FAD and FMN can vary significantly from source
to source so that the equilibrium constant of some indi-
vidual steps of different reductases can differ by orders
of magnitude (Murataliev et al., 2004).
The FMN2 Site
The FMN2 site lies at the interface of the flavodoxin and
connecting domains. It is exposed to the bulk solvent
and is far less conserved across the CPR gene family
than the FMN1 site (Figure 3). In fact, only the residues
Structure
54Figure 3. Sequence Alignment for the FMN Binding Sites in the CPR Gene Family
Residues constituting the FMN1 site are labeled with blue numbers, and residues constituting the FMN2 site are labeled with black numbers. The
arrows show the direction from the N terminus to the C terminus. Residues interacting with the pyrimidine edge of the FMN2 are enclosed in
green boxes. Alignment was performed for 44 CPR sequences by using BCM Search Launcher (Smith et al., 1996; http://searchlauncher.bcm.
tmc.edu/multi-align/multi-align.html). The figure was generated with ESPript (Gouet et al., 1999).binding the FMN2 ribityl moiety, T71 and D187, are in-
variant in all CPRs. Binding to the isoalloxazine ring
shows phyla-specific variations, which potentially may
tune the isoalloxazine ring system to its change in redox
potential and reactivity in different CPRs. At the hydro-
philic pyrimidine edge of the FMN2, charged side chains
of residues D74 and K78 are within hydrogen bond dis-
tance of the flavin N3 (2.5 A˚) and O4 atoms (3.2 A˚), re-
spectively (Figures 4B and 5). Negative and positive
charges at residues 74 and 78, respectively, are remark-
ably conserved throughout all CPR species except plant
forms, where these positions are occupied by glycine
and alanine, respectively (Figure 3).
On the re face of the FMN2 isoalloxazine ring, the
electronegative Y75 hydroxyl oxygen is centered 3.3 A˚
above the plane of the central ring (Figures 4B and 5).
Y75 is conserved in fungi, but it is substituted by phenyl-
alanine in plants and vertebrates and by methionine in
nematodes (Figure 3). On the si face, the electron-rich
carbonyl oxygen of P365 points at N5 in FMN2 (3.15 A˚),
defining an angle with the isoalloxazine plane of 110º.
The FMN2 ribityl moiety is hydrogen bonded to the car-
boxyl group of D187 (2.8 A˚ and 2.5 A˚), and this, in turn, is
hydrogen bonded to T71 (3.5 A˚) (Figures 4B and 5). There
are no direct contacts between the FMN2 phosphate
group and the protein in the crystal structure. The elec-tron density for FMN2 is progressively less defined to-
ward the phosphate end (Figure 4B). There appears to
be enough space in the FMN2 site to accommodate ei-
ther FMN or FAD. Therefore, to exclude FAD as a third fla-
vin cofactor, crystallization of yCPR was also performed
with the addition of only FAD. This resulted in crystals
containing an empty FMN2 site, yet the FMN1 site was
fully occupied. This fact indicates that the third flavin co-
factor bound within yCPR in the crystal is indeed an FMN;
the less tight binding of FMN2 is likely due to high acces-
sibility of the FMN2 site at the protein surface.
Flavin Binding in yCPR and Other Flavoproteins
Protein-cofactor interactions observed in the FMN2 site
are not random; they are also found in other flavopro-
teins of diverse functions. Specifically, a positive charge
at the pyrimidine edge of the isoalloxazine ring is func-
tionally relevant because it can stabilize an anionic form
of the reduced flavin and increase the redox potential
of the cofactor (Ghisla and Massey, 1989). The flavopro-
teins in Table 1 stabilize anionic semiquinone intermedi-
ates of the flavin through contact (<3.5 A˚ distance) with
a positive charge—either fully charged side chains of
lysine or arginine, or the partially charged N terminus
of the a helix or a cluster of peptide nitrogens. Thus,
a positive charge at K78 may compensate for the
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(A and B) Stereoviews of the (A) FMN1 and
(B) FMN2 sites. Shown are residues that are
within 4 A˚ of FMNs. The electron density is
from the 2Fo 2 Fc composite omit map con-
toured at 1.3s. Stretches of the protein back-
bone in the FMN1 site are shown in green.negative charge at the C4-O4 locus of the putative an-
ionic semiquinone in the FMN2 site. The flavin N3 atom
is commonly found to be hydrogen bonded to proteins,
mostly via backbone carbonyl groups and more rarely
via amino acid side chains (Becker and Thomas, 2001;
Bradley and Swenson, 2001; Fox and Karplus, 1994;
Komori et al., 2001; Xia and Mathews, 1990). In yCPR,
N3 is hydrogen bonded to D74. In addition, p-p stacking
interactions of the electron-rich backbone carbonyl
oxygen (P365) with the flavin N5 atom and of the electro-
negative tyrosine (Y75) with a highly electropositive cen-
tral ring of the isoalloxazine are observed in many flavo-
proteins. Thus, the presence of a second FMN cofactor
in the yCPR crystals may reveal occupancy of a func-
tional site. Nevertheless, discovery of a second FMN
binding site in an electron transporter like CPR that has
been studied extensively is surprising and leaves room
for concern that this is a possible artifact of crystalliza-
tion. Questions that arise beyond this concern are: is
the FMN2 site functionally important? How many FMN
molecules function in the yCPR? Do other CPRs, includ-
ing the previously crystallized rCPR, have a second FMN
binding site? To begin to look for answers, we have per-
formed additional experiments and have further ana-
lyzed the yCPR structure and sequence similarity in
the CPR gene family.
All CPRs studied to date have an equimolar FAD:FMN
ratio. Analysis of the cofactor content in yCPR also re-
veals an equimolar protein:FMN:FAD ratio, indicating
occupancy of apparently only the FMN1 site. The puri-
fied protein is functionally active without added FMN,
which leads to the conclusion that one FMN molecule
is sufficient for yCPR to transfer electrons to P450s. Re-duction of excess cytochrome c with the yCPR/NADPH,
both in equimolar ratio, generates two reduced cyto-
chrome c molecules per one consumed NADPH, indicat-
ing that no priming with NADPH is required and that
one- and two-electron-reduced states of yCPR donate
electrons to the acceptor. For the FMN2 site to be func-
tionally active, a single FMN has to shuttle between both
FMN sites. Thus, occupancy of both FMN sites at the
same time must be due to the high concentrations of ex-
ternally added FMN and the ammonium sulfate in crys-
tallization conditions. From the analysis of the yCPR
structure with added FMN, all three flavin cofactors are
bound within the empty spacious protein interior that
is largely protected from the bulk solvent (Figures 2A
and 2B). The relative orientation of both FMN molecules
indicates roughly 2-fold rotation symmetry with an axis
going through the invariant D187 (Figure 5). For reloca-
tion from the FMN1 to the FMN2 site to occur, FMN
would have to swing along the interface between the
FMN and FAD/NADPH binding domains within the pro-
tein interior, thus circumscribing about half of a circle
with a 10 A˚ radius around the invariant D187 as a center
of rotation. At the same time, the FMN isoalloxazine ring
should rotate about 45º in one direction, and the phos-
phate group should rotate about 90º in another direction
around the ribityl side chain. During this relocation, the
ribityl moiety of FMN would remain within the interaction
distances from the carboxyl of D187, which is held in po-
sition by hydrogen bonding with the T71. As a result of
this transition between the FMN1 and the FMN2 sites,
the FMN N5-reference atom would relocate w20 A˚,
and the 8-CH3 group would relocate w16 A˚ (Figure 5).
There is enough space within the protein interior to
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FMN from the reductase. Mutation of D187 and T71 to
alanine in yCPR results in almost complete loss of
functional activity toward CYP51 (Figure 1C), although
activity toward cytochrome c remains unchanged. The
concept of flavin motion as an integral part of the cata-
lytic function has been developed for p-hydroxyben-
zoate hydroxylase from Preudomonas aeruginosa and
Pseudomonas fluorescens and related flavoprotein
monooxygenases that catalyze hydroxylation of the aro-
matic ring of a substrate (Entsch et al., 2005). Movement
Figure 5. Relative Orientation of FMN1 and FMN2 in yCPR
The orientation of FMN1 (blue) and FMN2 (red) in the structure
shows roughly 2-fold rotation symmetry with an axis going through
D187. The numbers of angstroms in blue indicate the distances be-
tween interacting atoms. The numbers of angstroms in black indi-
cate the distances between the N5-reference atom in FMN and a pu-
tative center of rotation, D187. FAD is yellow; the yCPR domains are
opaque and are highlighted according to the color scheme in Fig-
ure 1. The only clearly visible portion of the FMN2 is the 8-CH3 group
that points toward the bulk solvent.of the flavin between out and in conformations (7–8 A˚) in
this enzyme occurs by rotation of the isoalloxazine ring
about the ribityl side chain in the plane of the ring and
is necessary for reduction by NADPH (out conformation)
followed by reaction with oxygen (in conformation) to
form a flavin-C4a-hydroperoxide, an active form of oxy-
gen in flavoprotein hydroxylases.
Hypothetical Structure-Based Mechanism
of Electron Transfer in yCPR
The function of CPR is to split two reducing equivalents
obtained from NADPH and deliver them to P450 and
other acceptor proteins in two one-electron transfer
steps. NADPH reduces FAD that, in turn, transfers elec-
trons to FMN. The latter serves as a mediator that deliv-
ers electrons to P450. Access to the CPR surface for
FMN seems to be necessary to permit delivery of elec-
trons to target proteins. The presence of the two FMN
binding sites in yCPR with different environments and
accessibilities, and the requirement of only one FMN
molecule for electron transfer to P450, leads to a hypoth-
esis that yCPR performs its function through a mecha-
nism similar to p-hydroxybenzoate hydroxylase, shut-
tling a single FMN cofactor between two FMN binding
sites. Exposure of the 8-CH3 group of FMN2 to the
bulk solvent between negatively charged clusters of res-
idues involved in protein-acceptor binding suggests
that the FMN2 site is a port of exit of yCPR electrons.
We hypothesize that CPR cycles in a 0-2-1-0 se-
quence, where the numbers indicate the number of elec-
trons residing on the flavins (Figure 6). NADPH binds to
oxidized reductase (a), and hydride-ion transfer occurs
with transient formation of a charge-transfer complex
(b). As a result of intracomplex electron transfer, FMN
bound in the first site obtains one electron from FADH
and, upon FMN- protonation, both become neutral
(blue) semiquinones, FADH and FMNH (c). The neutral
FMNH semiquinone swings along the interface be-
tween the FMN and FAD/NADPH binding domains to the
FMN2 site as described above (Figure 5). In the secondTable 1. Binding Features of the Pyrimidine Edge of the Isoalloxazine Ring in Flavoproteins of Diverse Functions
Flavoenzyme Cofactor
PDB ID
Code
C2-O2
Contacts
C2-O4
Contacts References
Old yellow enzyme FMN 1OYB R243 (Fox and Karplus, 1994; Nakamura et al.,
1965)
Flavocytochrome b2 FMN 1FCB K349 (Xia and Mathews, 1990)
Trimethylamine
dehydrogenase
FMN 2TMD R222 (Anderson et al., 2000)
Glycolate oxidase FMN 1GOX K230 (Massey, 1995)
D-amino acid oxidase FAD 1DDO a helix (Massey, 1995)
Cholesterol oxidase
(type I)
FAD 1COY a helix (Martinez et al., 1997; Sampson and Vrielink,
2003)
Cholesterol oxidase
(type II)
FAD 1I19 R477 (Martinez et al., 1997; Sampson and Vrielink,
2003)
Monoamine oxidase FAD 1OJA N-S59, N-Y60 (Yue et al., 1993)
Medium-chain-acylCoA
dehydrogenase
FAD 3MDE N-V135, N-T136 (Mizzer and Thorpe, 1981)
Electron transfer flavoprotein FAD 1EFV N-R249, H286 N-Q265, N-T266,
N-G267
(Byron et al., 1989; Davidson et al., 1986;
Dwyer et al., 1999)
Cytochrome b5 reductase FAD 1UMK N-K110
(Iyanagi et al., 1984; Kobayashi et al.,
1988)
DNA photolyase FAD 1IQR R248 (Schleicher et al., 2005)
Proline dehydrogenase FAD 1K87 R431 (Becker and Thomas, 2001)
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57site, upon deprotonation, the neutral FMNH semiqui-
none presumably becomes an anionic FMN- semiqui-
none, and the negative charge on C4-O4 is stabilized
via the invariant positive charge at position 78 (d); it is
in this form that the FMN- semiquinone donates the first
electron to an acceptor. While FMN- delivers the first
electron, the second electron is stored in the form of a
neutral FADH semiquinone. To obtain the second elec-
tron, oxidized FMN must swing back to the FMN1 site (e);
obtain the second electron from the neutral FADH semi-
quinone to become a neutral FMNH semiquinone, leav-
ing FAD in an oxidized form (f); and repeat translocation
to the FMN2–site, becoming, once again, an anionic
FMN- semiquinone (g). Here, FMN- donates the second
electron to the acceptor and returns back to the FMN1
site to regenerate a fully oxidized flavoprotein (h). Fi-
nally, NADP+ dissociates from the complex (in principal,
NADP+ could leave at any stage from [c] onward).
We speculate that the proposed translocation of FMN
may be driven by a flow of the electrons, which must be
strictly coupled with protonation-deprotonation of the
FMN isoalloxazine ring and relocation of the FMN from
one FMN binding site to another. Each time FMN re-
ceives or donates an electron, it must relocate to an al-
ternative FMN binding site due to the different amino
acid environments of each site, which may be designed
to accommodate different electronic forms of the FMN.
In vitro, once an electron is released from the semiqui-
none in the FMN2 site, oxidized FMN may occasionally
dissociate from CPR due to more pronounced exposure
of the FMN2 site to the bulk solvent and its presumably
reduced affinity for the neutral FMN species. Thus, the
proposed mechanism explains the well-documented
phenomenon that FMN, in contrast to FAD, can be re-
versibly released from CPR, while, to release FAD,
CPR has to be partially denatured (Nisimoto and Shi-
bata, 1982; Vermilion and Coon, 1978). Two questions
A
B
Figure 6. Hypothetical Mechanism of Electron Transfer by P450 Re-
ductases
(A) Single catalytic turnover of yCPR. Neutral semiquinone is shown
in blue, and putative anionic semiquinone is shown in red.
(B) Structures of oxidized and semiquinone states of the isoalloxa-
zine system shown with the si side facing the viewer.arise: How high is the energy barrier for FMN transloca-
tion? To what degree do structural fluctuations in CPR
facilitate the FMN shuttling? The observation that a sin-
gle hydrogen bond formed between the flavin and the
hydroxyl group of the substrate analog shifts the isoal-
loxazine to the out position in p-hydroxybenzoate hy-
droxylase highlights the small energy barriers for such
changes in that enzyme (Entsch et al., 2005). In yCPR,
the ribityl side chain of the FMN apparently preserves
contacts with D187 upon translocation to the FMN2
site. The isoalloxazine ring could relocate in a different
environment with multiple interactions with the protein
side chains, which are not necessarily weaker than
those in the FMN1 site considering the fact that FMN
may have different electronic states in each site. FMN
phosphate is hydrogen bonded to the hydroxyl of the
side chains and the amide nitrogen of the backbone in
the FMN1 site, and no electrostatic interactions com-
pensate for the negative charge of the phosphate group.
Contacts between the FMN2 phosphate group and
yCPR are missing in the current structure. We anticipate
that in the case of physiological occupancy of the FMN2
site, which we believe suggests an empty FMN1 site,
some conformational changes may occur to facilitate
the formation of such contacts and to lower the energy
barrier for the FMN translocation.
Table 2. Crystallographic Data and Statistics
Data Set Se-Met+FMN Native2FMN
PDB ID 2BF4 2BN4
Data Collection
Wavelength, A˚ 0.97940 0.97918
Resolution, A˚ 3.0 2.9
Unique reflections 65,903 33,851
Redundancya 7.6 (4.7) 5.4 (4.7)
Coverage, % 99.9 (92.8) 94.4 (75.8)
Space group P212121 P212121
Unit cell (a, b, c), A˚ 77.75, 87.09,
259.59
78.14, 77.84,
261.49
Rsym
b, % 5.8 (30.1) 11.0 (50.6)
I/s 28.0 (4.3) 16.9 (2.0)
SAD Phasing Statistics
Number of used sites 18
Phasing powerc 1.69
Figure of merit after phasing 0.31
Quality of Model
Protein atoms 10,148 10,028
Heterogen atoms 325 248
Solvent atoms 151 55
Mean B factor, A˚2 53.1 66.7
Rcryst (Rfree)
d, % 19.7/26.1 23.3/30.0
Rms deviation
Bonds, A˚ 0.008 0.008
Angles, º 1.4 1.5
a Numbers in parentheses correspond to the highest-resolution
shell.
b Rsym = SjIi 2 <I>j/SIi, where Ii is the intensity of the ith observation,
and <I> is the mean intensity of reflection.
c Phasing power = <Fh>/E, in which <Fh> is the root mean square
heavy atom structure factor, and E is the residual lack of closure.
d Rcryst = S kFoj 2 jFck/SjFoj, calculated with the working reflection
set. Rfree is the same as Rcryst, but it is calculated with the reserved
reflection set.
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Reductases
The nature of the active form of FMN is one of the main
controversies between mechanisms of electron trans-
fer in mammalian versus other P450 monooxygenase
systems. Data obtained on the reductases competent
in physiological electron transfer to P450s, including
house fly CPR (Murataliev et al., 1999; Murataliev and
Feyereisen, 1999) and P450BM3 reductase (Murataliev
et al., 1997; Sevrioukova et al., 1996a), indicate a 0-2-
1-0 cycling sequence for the reductase reduction state,
no need for a priming reaction, donation of electrons
from the FMN semiquinone, and formation of two types
of FMN semiquinone. All of these features are present in
the structure-based mechanism proposed herein. In
contrast, two different mechanisms are proposed for
mammalian reductases with the enzyme reduction state
cycling through 1-3-2-1 or 2-4-3-2 sequences (Backes,
1993). Both mechanisms require a priming reaction
with NADPH to bring the reduction state of the flavopro-
tein to either 3 or 4 before any electron transfer from
FMN to an acceptor can occur, implying that the FMN
hydroquinone, but not its semiquinone, serves as a
donor of both electrons. All one-electron-reduced CPRs
can stabilize an air-stable, neutral semiquinone that
does not efficiently reduce P450 or cytochrone c
(Backes, 1993; Murataliev et al., 2004). Analysis of avail-
able data on microsomal CPRs presented in Murataliev
et al. (2004) indicates a number of observations that dis-
agree with either of the mechanisms proposed for mam-
malian CPR and suggests that a catalytic role for an FMN
semiquinone in mammalian CPRs may have been largely
overlooked. The absence of FMN in the FMN2 site in the
rCPR may be directly related to the inability of N-termi-
nal-truncated mammalian CPRs to perform physiologi-
cally relevant electron transfer (Backes, 1993; Hayashi
et al., 2003). Apparently, N-terminal truncation of yCPR
does not have such a severe impact on its functional ac-
tivity, although the exact reason for this is unknown.
The yCPR structure has revealed a second FMN bind-
ing site in the interface of the connecting and the FMN
binding domains. The two FMN binding sites have differ-
ent accessibilities and amino acid environments, the lat-
ter suggesting stabilization of different electronic forms
of flavin semiquinone: neural (blue) in FMN1 sites and
anionic (red) in FMN2 sites. Considering the fact that
only one FMN molecule is required for function, a hypo-
thetical structure-based mechanism is proposed that in-
cludes FMN shuttling between the two sites as a novel,
to our knowledge, feature. Given the complexity of elec-
tron transfer in CPR, a full understanding of the func-
tional role of this newly, to our knowledge, discovered
site and applicability of the proposed mechanism will
require further crystallographic analysis and thermody-
namic measurements on the CPR with specifically de-
signed mutants, as well as kinetic measurements di-
rected at elucidating the order of events. The results
presented here provide testable hypotheses for new ex-
periments to address each aspect of the mechanism of
intramolecular electron transfer in yCPR. UV-Vis, stop-
ped-flow, fluorescence, and EPR spectrophotometric
approaches will be used to attempt assignment of dis-
tinct spectroscopic signatures to the various binding
and redox configurations of FMN and FAD. Anaerobicstopped-flow studies with an OLIS RSM-1000 instru-
ment will give a set of complete UV-Vis spectra as a func-
tion of time, which in addition to analysis by singular
value decomposition should be specific to the number
of absorbing species if not their identities. EPR spec-
troscopy, which will be used to detect FMN semiqui-
none radicals, can distinguish between the neutral and
anionic forms of FMN semiquinone and may be able to
distinguish different binding environments. Mutants
with targeted ability to shuttle FMN or with changed en-
vironment in the FMN2 site are generated as compara-
tive companions of the wild-type yCPR for these stud-
ies. Another direction that we will pursue is screening
for the potential CPR inhibitors that bind in the FMN2
site. To rapidly screen a large number of compounds,
we adapted a fluorescence assay (Prough et al., 1978)
utilizing the ability of CYP1A2 to convert 7-methoxyre-
sorufin tofluorescent resorufin.TheyCPRinhibitors iden-
tified as a result of screening will be used in functional
assays to refine our understanding of another aspect
of the mechanism: intermolecular electron transfer be-
tween CPR and protein acceptors. We believe that the
discovery of the second FMN binding site will change
the current understanding of CPR structure-function and
lead to resolution of mechanistic controversies between
different CPR families. The understanding of these pro-
cesses will have more widespread implications because
other diflavin reductases, e.g., nitric oxide synthase and
methionine synthase reductase, are highly homologous
genetically, structurally, and functionally.
Experimental Procedures
Activity of Truncated yCPR in Reconstituted Assays
The truncated form of yCPR lacking 33 residues, including the N-ter-
minal hydrophobic membrane anchor, and containing 6 N-terminal
histidine residues preceded by 4 and followed by 15 residues from
the cloning site (Venkateswarlu et al., 1998) was expressed in
E. coli and was purified to homogeneity by affinity chromatography
on Ni-NTA agarose (Qiagen), followed by ion-exchange chromatog-
raphy on S-Sepharose and Q-Sepharose (both from Amersham
Pharmacia Biotech).
Functional activity assays were performed with human sterol 14a-
demethylase (CYP51), rabbit CYP1A2 with 7-methoxyresorufin as
a substrate, and cytochrome c. The reaction of lanosterol 14a-de-
methylation was carried out at a 1:2 P450:CPR molar ratio. Samples
contained 2 mM CYP51, 50 mM lanosterol (cold/[3-3H] [American Ra-
diolabeled Chemicals, Inc.] mixture, 105 cpm), 100 mM dilauroyl-a
phosphatidylcholine, 0.4 mg/ml isocitrate dehydrogenase, 25 mM
sodium isocitrate, and 5 mM NADPH in 0.5 ml of 20 mM MOPS
(pH 7.4), 50 mM KCl, 5 mM MgCl2, 10% (v/v) glycerol. The reaction
was terminated after 20 min of incubation at 37ºC by the addition
of ethyl acetate, and sterols were subsequently extracted. The
enzyme-derived products were analyzed by reverse-phase (C18)
HPLC (Waters Corporation, USA) equipped with a b-RAM Detector
(Inus Systems, Inc., USA) by using a linear gradient of acetonitrile:
water:methanol (4.5:1:4.5)/methanol as a mobile phase at the flow
rate of 1.5 ml/min.
The enzymatic reaction of O-demethylation of 7-methoxyresorufin
by CYP1A2 was carried out at a variety of yCPR concentrations as
indicated in Figure 1B. Samples contained 20 mM CYP1A2, 50 mM
7-methoxyresorufin, 100 mM dilauroyl-a phosphatidylcholine, and
5 mM NADPH in 100 ml of 20 mM K-phosphate (pH 7.5). The reaction
was terminated after 20 min of incubation at 37ºC by the addition of
100 ml methanol. Product formation was monitored by a fluorometric
assay (Prough et al., 1978) (excitation 544 nm, emission 590 nm) by
using a FLUOstar automated microplate reader (BMG Lab Technol-
ogies GmbH, Germany). Rabbit CYP1A2 and 7-methoxyresorufin
were kind gifts of F.P. Guengerich.
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D187A mutants was carried out in 1 ml of 100 mM K-phosphate
buffer (pH 7.7) containing 10 mM reductase and 40 mM cytochrome
c. Reactions were initiated by adding NADPH to 10 mM concentra-
tion. Accumulation of reduced cytochrome c was monitored by vis-
ible light spectroscopy at 550 nm by using 3 = 21,000 M21cm21. Two
molecules of cytochrome c were reduced per one NADPH molecule
consumed during a reaction driven by the wild-type and both mu-
tants.
Stoichiometry of Flavin Cofactors
yCPR was denatured by heating at 95ºC for 30 min, the precipitate
was removed by centrifugation, and the supernatant was analyzed
isocratically by reverse-phase HPLC (Waters Corporation, USA)
equipped with a 996 Photodiode Detector by using 10 mM diammo-
nium hydrogen phosphate (pH 5.5):acetonitrile (10:1.2) (Pietta et al.,
1982) as a mobile phase at the flow rate of 1.0 ml/min. The content
and ratio of cofactors were determined with calibration curves
from the HPLC profiles at 473 nm by using 3 = 9200 M21cm21 for
both FMN and FAD (Aliverti et al., 1999). Protein concentration was
measured with the BCA Protein Assay Reagent (Pierce). The ratios
of protein/FMN/FAD obtained from two experiments are 1.0:0.9:1.0
and 1.0:1.1:1.2.
Crystallization and Data Collection
Crystals of yCPR were obtained in the presence of externally added
cofactors, FMN, FAD, and NADPH, at 1 mM concentrations. Alterna-
tively, FMN was omitted, while FAD and NADPH were added. Two
crystal forms belonging to the orthorhombic P212121 space group
with different unit cell parameters (Table 2) grew from 0.2 mM
yCPR, in a selenomethionine-derived or native form, in 10 mM Tris-
HCl (pH 7.5), 100 mM NaCl in a hanging drop equilibrated against
1.6 M ammonium sulfate in 100 mM sodium citrate buffer (pH 5.0).
Native and single anomalous dispersion diffraction data (Table 2)
were collected at 100–110 K at the Southeast Regional Collaborative
Access Team (SER-CAT) 22ID and Structural Biology Center 19ID
beamlines, Advanced Photon Source, Argonne National Laboratory,
USA.
Phasing and Refinement
The images were integrated, and the intensities were merged by us-
ing HKL2000 (Otwinowski and Minor, 1997). The positions of seleno-
methionine sites were determined for the first crystal form by using
the SAD protocol in CNS (Brunger et al., 1998). The phases were cal-
culated and improved by CNS, yielding an interpretable electron
density map at 3.0 A˚ resolution. The structure of the second crystal
form with no added FMN was determined by molecular replacement
to a resolution of 2.9 A˚. The final atomic models (Table 2) were ob-
tained after 15 and 6 iterations of refinement (CNS [Brunger et al.,
1998]) and manual model building with the program O (Jones et al.,
1991), respectively.
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